E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
TL;DR: Nilotinib induces high and rapid rates of cytogenetic and molecular response, with less progression to advanced forms of disease compared with imatinib, considering that the rapid achievement of these clinical milestones has been associated with positive long-term outcomes.
Journal ArticleDOI
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level
Hagop M. Kantarjian,Wendy Stock,Ryan D. Cassaday,Daniel J. DeAngelo,Elias Jabbour,Susan O'Brien,Matthias Stelljes,Tao Wang,Luisa Paccagnella,Kevin Nguyen,Barbara Sleight,Erik Vandendries,A. Douglas Laird,Anjali S. Advani +13 more
TL;DR: The greatest benefit from treatment with InO was observed in those patients with CD22Positivity ≥90%, while statistical differences in PFS, DOR, and OS could not be shown in patients withCD22 positivity.
Journal ArticleDOI
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors
Elias Jabbour,Koji Sasaki,F. Haddad,Ghayas C Issa,Guillermo Garcia-Manero,Tapan M. Kadia,Nitin Jain,Musa Yilmaz,Courtney D. DiNardo,Keyur Patel,Rashmi Kanagal-Shamanna,Richard E. Champlin,Issa F. Khouri,Sara Dellasala,Sherry Pierce,Hagop M. Kantarjian +15 more
TL;DR: In this paper , the authors performed a propensity score matching analysis to compare outcomes and multivariate analysis to identify variables associated with survival, and concluded that ponatinib is the only independent factor associated with better survival.
Journal ArticleDOI
Dasatinib for the treatment of chronic myeloid leukemia
TL;DR: The ability of dasatinib to induce rapid and high rates of response with a low progression to advanced forms of CML may translate into improvements in survival.
Journal ArticleDOI
Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Koji Sasaki,Elias Jabbour,Susan O'Brien,Farhad Ravandi,Deborah A. Thomas,Tapan M. Kadia,Guillermo Garcia-Manero,Jan A. Burger,Naveen Pemmaraju,Yesid Alvarado,Naval Daver,Nitin Jain,Marina Konopleva,Richard E. Champlin,Issa F. Khouri,Partow Kebriaei,David Marin,Courtney D. DiNardo,Zeev Estrov,Koichi Takahashi,Nicholas J. Short,Maria Khouri,Jovitta Jacob,Rebecca Garris,Jorge E. Cortes,Hagop M. Kantarjian +25 more
TL;DR: Evaluation of response rate, progression-free survival, overall survival, and safety of single-agent INO in R/R ALL to assess the safety of this regimen found it to be effective and safe.